THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 20, 2022 | $3,350,000 | Replaced |
| 4th Quarter - Report | Jan 20, 2022 | $3,350,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Postal POS
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| GARY J KLINE | — |
| JAYMI DOREEN LIGHT | — |
Defense DEF
* Pharmacy issues related to TRICARE and S. 1605/H.R. 4350, National Defense Authorization Act (NDAA) for Fiscal Year 2022 (P.L. 117-81).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| GARY J KLINE | — |
Health Issues HCR
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JAYMI DOREEN LIGHT | — |
Medicare/Medicaid MMM
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JAYMI DOREEN LIGHT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.